DrugDashboards

Diltiazem Hydrochloride

Diltiazem Hydrochloride · DILTIAZEM HYDROCHLORIDE 120 mg/1 · Capsule, Extended Release · Oral · Glenmark Pharmaceuticals Inc., Usa

NDC 68462-0562-01 · 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE · ANDA · View full market →

The short version

13 companies supply this market — deep enough that no single failure threatens the supply. The price is down 17% over the past year, to $1.98 per unit. One of its named manufacturing plants, Glenmark Pharmaceuticals Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 50742-0248-90) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$0.3386per unit
middle half $0.2355–$0.3814 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.3386
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 2 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$2.00$4.00Apr 2021Sep 2026$1.98
55 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$59.38
#90 count
$178.15

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$66,029
376 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

8● Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • price down 21% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for diltiazem hydrochloride (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA212317
TE code
AB1
Approval date
Mar 22, 2021
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingMar 13, 2025
    Glenmark Pharmaceuticals Inc., USA — CGMP Deviations
  • Class II · OngoingNov 1, 2024
    Glenmark Pharmaceuticals Inc., USA — cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
  • Class II · OngoingNov 1, 2024
    Glenmark Pharmaceuticals Inc., USA — cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
  • Class II · OngoingNov 1, 2024
    Glenmark Pharmaceuticals Inc., USA — cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
  • Class II · OngoingApr 17, 2024
    Glenmark Pharmaceuticals Inc., USA — Failed Dissolution Specifications
  • Class II · OngoingMar 26, 2024
    Glenmark Pharmaceuticals Inc., USA — Failed Dissolution Specifications: Out of Specification (OOS) was reported in test of dissolution at the 12th month time point in long term stability study.

Manufacturers of Diltiazem Hydrochloride (Capsule, Extended Release)

LabelerStrengthFirst seenLast seen
Alembic Pharmaceuticals Inc.DILTIAZEM HYDROCHLORIDE 180 mg/1Jul 15, 2026Sep 3, 2026
Alembic Pharmaceuticals Inc.DILTIAZEM HYDROCHLORIDE 240 mg/1Jul 15, 2026Sep 3, 2026
Alembic Pharmaceuticals Inc.DILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 3, 2026
Alembic Pharmaceuticals LimitedDILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackDILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackDILTIAZEM HYDROCHLORIDE 180 mg/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackDILTIAZEM HYDROCHLORIDE 360 mg/1Jul 15, 2026Sep 3, 2026
Golden State Medical Supply, Inc.DILTIAZEM HYDROCHLORIDE 360 mg/1Sep 3, 2026Sep 3, 2026
Sun Pharmaceutical Industries, Inc.DILTIAZEM HYDROCHLORIDE 240 mg/1Jul 15, 2026Sep 3, 2026
Sun Pharmaceutical Industries, Inc.DILTIAZEM HYDROCHLORIDE 300 mg/1Jul 15, 2026Sep 3, 2026
Sun Pharmaceutical Industries, Inc.DILTIAZEM HYDROCHLORIDE 180 mg/1Jul 15, 2026Sep 3, 2026
Sun Pharmaceutical Industries, Inc.DILTIAZEM HYDROCHLORIDE 360 mg/1Jul 15, 2026Sep 3, 2026
Upsher-Smith Laboratories, LLCDILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 3, 2026
Zydus Lifesciences LimitedDILTIAZEM HYDROCHLORIDE 360 mg/1Jul 15, 2026Sep 3, 2026
Zydus Lifesciences LimitedDILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 3, 2026
Zydus Pharmaceuticals (USA) Inc.DILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 3, 2026
Zydus Pharmaceuticals (USA) Inc.DILTIAZEM HYDROCHLORIDE 240 mg/1Jul 15, 2026Sep 3, 2026
Zydus Pharmaceuticals (USA) Inc.DILTIAZEM HYDROCHLORIDE 180 mg/1Jul 15, 2026Sep 3, 2026
Zydus Pharmaceuticals (USA) Inc.DILTIAZEM HYDROCHLORIDE 300 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsDILTIAZEM HYDROCHLORIDE 240 mg/1Jul 15, 2026Sep 2, 2026
A-S Medication SolutionsDILTIAZEM HYDROCHLORIDE 180 mg/1Jul 15, 2026Sep 2, 2026
A-S Medication SolutionsDILTIAZEM HCL 240 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare, Inc.DILTIAZEM HYDROCHLORIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare, Inc.DILTIAZEM HYDROCHLORIDE 240 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare, Inc.DILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 2, 2026
Actavis Pharma, Inc.DILTIAZEM HYDROCHLORIDE 240 mg/1Jul 15, 2026Sep 2, 2026
Actavis Pharma, Inc.DILTIAZEM HYDROCHLORIDE 300 mg/1Jul 15, 2026Sep 2, 2026
Actavis Pharma, Inc.DILTIAZEM HYDROCHLORIDE 360 mg/1Jul 15, 2026Sep 2, 2026
Actavis Pharma, Inc.DILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 2, 2026
Actavis Pharma, Inc.DILTIAZEM HYDROCHLORIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.DILTIAZEM HYDROCHLORIDE 300 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.DILTIAZEM HYDROCHLORIDE 360 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedDILTIAZEM HYDROCHLORIDE 360 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedDILTIAZEM HYDROCHLORIDE 300 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.DILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.DILTIAZEM HYDROCHLORIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.DILTIAZEM HYDROCHLORIDE 240 mg/1Jul 15, 2026Sep 2, 2026
AvKAREDILTIAZEM HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
AvKAREDILTIAZEM HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 2, 2026
AvKAREDILTIAZEM HYDROCHLORIDE 90 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Diltiazem Hydrochloride — NDC 68462-0562-01," retrieved September 3, 2026, https://drugdashboards.com/drug/68462056201.

Free to cite with attribution — see how the data is put together.